Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes — for most people, stopping Wegovy leads to significant weight regain. Clinical trials show that around two-thirds of the weight lost during treatment returns within a year of stopping semaglutide, because the medicine's appetite-suppressing effects end when it leaves your system. That's a hard truth, and if you're weighing up whether to start or how long to continue, it's a reasonable thing to want to understand fully before you decide. Wegovy is a prescription-only medicine and any decision about continuing, pausing or stopping treatment should be made with your prescriber, not in isolation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy works by activating GLP-1 receptors in the brain and gut. This slows gastric emptying, reduces hunger signals and increases the sense of fullness after eating. The result is a lower calorie intake with noticeably less effort. What the medicine does not do is permanently reset the body's weight regulation system.
When you stop taking semaglutide, those receptor effects stop within days to weeks as the drug clears your system. Hunger returns to where it was before treatment (sometimes sharply, sometimes gradually) because the underlying biology hasn't changed. For many people, that means eating more without meaning to, particularly in the first few months after stopping. The body also has compensatory mechanisms that defend a higher weight set point, and these reassert themselves once the pharmacological check on appetite is removed.
This isn't a personal failing. Weight is shaped far more by biology than by willpower, and obesity is recognised as a chronic condition by bodies including the NHS. What it does mean is that Wegovy, like many treatments for chronic conditions, needs to be thought of in the context of long-term management rather than a short course.
The STEP 1 extension study followed participants who had completed the main 68-week semaglutide trial. After stopping treatment, participants regained, on average, around two-thirds of the weight they had lost within 12 months, waist circumference, blood pressure and blood sugar levels also moved back towards pre-treatment values. The STEP 1 trial, published in the New England Journal of Medicine, had shown average weight reductions of around 15% during treatment, which contextualises how substantial that regain is in practice.
It's worth noting that not everyone regains at the same rate. Participants who had built consistent dietary habits and increased their physical activity during treatment tended to retain more of the loss. But the trial data make clear that lifestyle changes alone rarely fully offset what the medicine was doing. The question of whether continued treatment is right for you is exactly the kind of thing worth discussing with a prescriber before reaching the decision to stop.
There are details about how much weight typically returns after stopping Wegovy that go into the evidence further, if you want to read more before your next review.
One aspect of stopping that sometimes gets overlooked: it isn't only the number on the scale that reverses. Improvements to cardiovascular risk markers (blood pressure, triglycerides, HbA1c in people with type 2 diabetes) tracked closely alongside the weight loss during treatment and moved back towards baseline when it ended.
For people who started Wegovy partly because of a weight-related health condition, this matters. It reinforces why NICE's guidance and NHS England's advice on weight-management injections both frame these medicines as long-term treatments rather than fixed-course interventions, and why stopping without medical input carries real health implications beyond aesthetics.
If you're concerned about side effects that are prompting you to think about stopping, or if you're considering a break before surgery, your prescriber is the right person to talk through the timing and any bridging plan. You can also read about the different dose options within the Wegovy schedule, sometimes a lower maintenance dose is preferable to stopping entirely.
Stopping abruptly carries the regain risk described above. A structured approach with your prescriber might include stepping down to a lower dose, extending the titration schedule, or setting clear criteria for when to pause. None of these options eliminates regain risk, but they give you more control and clinical oversight during the transition.
Some people stop Wegovy because of cost. If that's a factor, it's worth understanding exactly what a private prescription includes (consultation, prescriber review, delivery, and aftercare support) because the routes available for obtaining Wegovy in the UK vary considerably in what they offer around the medicine itself. You can also compare the treatment options available if semaglutide isn't the right long-term fit.
If you are on Wegovy through a provider and want an independent clinical view, our prescribers review every patient's case personally, a real clinician reads your notes, not automated software. You can start a free consultation to discuss whether continuing, switching or pausing treatment makes sense for your situation. There's no obligation, and the conversation is clinical from the start. If you've already stopped and are noticing the scales creeping up, our page on why people gain weight back on Wegovy explains the mechanisms in more detail, and our guide on whether you put weight back on after Wegovy covers what the evidence says about how common and how significant that regain tends to be.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.